

Deirdre A Lane

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5079025/publications.pdf>

Version: 2024-02-01

349
papers

41,627
citations

5876

81
h-index

2558

195
g-index

360
all docs

360
docs citations

360
times ranked

26000
citing authors

#	ARTICLE	IF	CITATIONS
1	Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach. <i>Chest</i> , 2010, 137, 263-272.	0.4	5,657
2	2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). <i>European Heart Journal</i> , 2021, 42, 373-498.	1.0	5,583
3	A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation. <i>Chest</i> , 2010, 138, 1093-1100.	0.4	3,810
4	The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. <i>European Heart Journal</i> , 2018, 39, 1330-1393.	1.0	1,576
5	Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. <i>Europace</i> , 2015, 17, 1467-1507.	0.7	951
6	Comparative Validation of a Novel Risk Score for Predicting Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2011, 57, 173-180.	1.2	898
7	Antithrombotic Therapy for Atrial Fibrillation. <i>Chest</i> , 2012, 141, e531S-e575S.	0.4	891
8	Stroke and Bleeding in Atrial Fibrillation with Chronic Kidney Disease. <i>New England Journal of Medicine</i> , 2012, 367, 625-635.	13.9	795
9	Antithrombotic Therapy for Atrial Fibrillation. <i>Chest</i> , 2018, 154, 1121-1201.	0.4	718
10	2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. <i>Europace</i> , 2015, 17, euv319.	0.7	635
11	Quality of Life in Patients with Atrial Fibrillation: A Systematic Review. <i>American Journal of Medicine</i> , 2006, 119, 448.e1-448.e19.	0.6	502
12	2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. <i>Europace</i> , 2021, 23, 1612-1676.	0.7	494
13	Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm So. <i>European Heart Journal</i> , 2014, 35, 3155-3179.	1.0	490
14	Identifying Patients at High Risk for Stroke Despite Anticoagulation. <i>Stroke</i> , 2010, 41, 2731-2738.	1.0	448
15	Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a "real world" nationwide cohort study. <i>Thrombosis and Haemostasis</i> , 2011, 106, 739-749.	1.8	393
16	Mortality and Quality of Life 12 Months After Myocardial Infarction: Effects of Depression and Anxiety. <i>Psychosomatic Medicine</i> , 2001, 63, 221-230.	1.3	340
17	Atrial fibrillation. <i>Lancet</i> , The, 2012, 379, 648-661.	6.3	337
18	The Global Burden of Atrial Fibrillation and Stroke. <i>Chest</i> , 2012, 142, 1489-1498.	0.4	335

#	ARTICLE	IF	CITATIONS
19	Comorbidities associated with mortality in 31,461 adults with COVID-19 in the United States: A federated electronic medical record analysis. <i>PLoS Medicine</i> , 2020, 17, e1003321.	3.9	331
20	Use of the CHA ₂ DS ₂ -VASc and HAS-BLED Scores to Aid Decision Making for Thromboprophylaxis in Nonvalvular Atrial Fibrillation. <i>Circulation</i> , 2012, 126, 860-865.	1.6	327
21	Performance of the HEMORR2HAGES, ATRIA, and HAS-BLED Bleeding Risk "Prediction Scores in Patients With Atrial Fibrillation Undergoing Anticoagulation. <i>Journal of the American College of Cardiology</i> , 2012, 60, 861-867.	1.2	326
22	Mobile Photoplethysmographic Technology to Detect Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2365-2375.	1.2	294
23	Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a "real world" atrial fibrillation population: A modelling analysis based on a nationwide cohort study. <i>Thrombosis and Haemostasis</i> , 2012, 107, 584-589.	1.8	289
24	Assessment of the CHA ₂ DS ₂ -VASc Score in Predicting Ischemic Stroke, Thromboembolism, and Death in Patients With Heart Failure With and Without Atrial Fibrillation. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 1030.	3.8	262
25	Stroke Prevention in Atrial Fibrillation. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1950.	3.8	258
26	Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. <i>BMJ, The</i> , 2015, 351, h4451.	3.0	247
27	A comparison of risk stratification schemes for stroke in 79,884 atrial fibrillation patients in general practice. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 39-48.	1.9	240
28	Bleeding risk assessment and management in atrial fibrillation patients. <i>Thrombosis and Haemostasis</i> , 2011, 106, 997-1011..	1.8	234
29	Depression, Anxiety, and Quality of Life in Patients With Atrial Fibrillation. <i>Chest</i> , 2007, 132, 1259-1264.	0.4	232
30	Mobile Health Technology to Improve Care for Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1523-1534.	1.2	209
31	Screening for atrial fibrillation: a European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulaci3n Cardıaca y Electrofisiologıa (SOLAECE). <i>Europace</i> , 2017, 19, 1589-1623.	0.7	208
32	Age as a Risk Factor for Stroke in Atrial Fibrillation Patients. <i>Journal of the American College of Cardiology</i> , 2010, 56, 827-837.	1.2	206
33	Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. <i>Europace</i> , 2011, 13, 723-746.	0.7	197
34	The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. <i>Europace</i> , 2018, 20, 1231-1242.	0.7	194
35	Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options—a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference. <i>Europace</i> , 2012, 14, 8-27.	0.7	193
36	Severe Renal Impairment and Stroke Prevention in Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2011, 57, 1339-1348.	1.2	191

#	ARTICLE	IF	CITATIONS
37	Temporal Trends in Incidence, Prevalence, and Mortality of Atrial Fibrillation in Primary Care. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	187
38	Device-detected subclinical atrial tachyarrhythmias: definition, implications and management—an European Heart Rhythm Association (EHRA) consensus document, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). <i>Europace</i> , 2017, 19, 1556-1578.	0.7	186
39	Atrial fibrillation. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16016.	18.1	185
40	Mobile Health Technology for Atrial Fibrillation Management Integrating Decision Support, Education, and Patient Involvement: mAF App Trial. <i>American Journal of Medicine</i> , 2017, 130, 1388-1396.e6.	0.6	172
41	Adjusted prognostic association of depression following myocardial infarction with mortality and cardiovascular events: individual patient data meta-analysis. <i>British Journal of Psychiatry</i> , 2013, 203, 90-102.	1.7	166
42	Educational Intervention Improves Anticoagulation Control in Atrial Fibrillation Patients: The TREAT Randomised Trial. <i>PLoS ONE</i> , 2013, 8, e74037.	1.1	165
43	Atrial fibrillation and heart failure due to reduced versus preserved ejection fraction: A systematic review and meta-analysis of death and adverse outcomes. <i>International Journal of Cardiology</i> , 2016, 203, 660-666.	0.8	161
44	Adherence to oral anticoagulant therapy in patients with atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2017, 117, 209-218.	1.8	161
45	The prevalence and persistence of depression and anxiety following myocardial infarction. <i>British Journal of Health Psychology</i> , 2002, 7, 11-21.	1.9	159
46	Epidemiology of atrial fibrillation. <i>International Journal of Clinical Practice</i> , 2018, 72, e13070.	0.8	154
47	Patient knowledge and perceptions of atrial fibrillation and anticoagulant therapy: Effects of an educational intervention programme. <i>International Journal of Cardiology</i> , 2006, 110, 354-358.	0.8	152
48	Predictors of attendance at cardiac rehabilitation after myocardial infarction. <i>Journal of Psychosomatic Research</i> , 2001, 51, 497-501.	1.2	147
49	Additive Role of Plasma von Willebrand Factor Levels to Clinical Factors for Risk Stratification of Patients With Atrial Fibrillation. <i>Stroke</i> , 2006, 37, 2294-2300.	1.0	140
50	Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making—a position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. <i>Europace</i> , 2015, 17, 1169-1196.	0.7	138
51	Effects of depression and anxiety on mortality and quality-of-life 4 months after myocardial infarction. <i>Journal of Psychosomatic Research</i> , 2000, 49, 229-238.	1.2	137
52	Atrial Fibrillation and Cognitive Function. <i>Journal of the American College of Cardiology</i> , 2019, 73, 612-619.	1.2	133
53	Stroke and Thromboembolism in Atrial Fibrillation. <i>Circulation Journal</i> , 2012, 76, 2289-2304.	0.7	131
54	Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: a nationwide cohort study. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 495-504.	1.9	129

#	ARTICLE	IF	CITATIONS
55	Improved Outcomes by Integrated Care of Anticoagulated Patients with Atrial Fibrillation Using the Simple ABC (Atrial Fibrillation Better Care) Pathway. American Journal of Medicine, 2018, 131, 1359-1366.e6.	0.6	129
56	Personalized management of atrial fibrillation: Proceedings from the fourth Atrial Fibrillation competence NETWORK/European Heart Rhythm Association consensus conference. Europace, 2013, 15, 1540-1556.	0.7	125
57	Is female sex a risk factor for stroke and thromboembolism in patients with atrial fibrillation? A systematic review and meta-analysis. QJM - Monthly Journal of the Association of Physicians, 2014, 107, 955-967.	0.2	124
58	Effectiveness of Cognitive Behavioral Therapy for Depression and Anxiety in Patients With Cardiovascular Disease: A Systematic Review and Meta-Analysis. Psychosomatic Medicine, 2018, 80, 742-753.	1.3	123
59	A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference. Europace, 2016, 18, 37-50.	0.7	121
60	Cardiac tachyarrhythmias and patient values and preferences for their management: the European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulaci3n Card3aca y Electrofisiolog3a (SOLEACE). Europace, 2015, 17, 1747-1769.	0.7	119
61	European Heart Rhythm Association (EHRA) consensus document on the management of supraventricular arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulaci3n Cardiac y Electrofisiologia (SOLEACE). Europace, 2017, 19, 465-511.	0.7	118
62	Low-dose spironolactone in the management of resistant hypertension: a surveillance study. Journal of Hypertension, 2007, 25, 891-894.	0.3	116
63	A systematic review of the effects of acute psychological stress and physical activity on haemorrhage, coagulation, fibrinolysis and platelet reactivity: Implications for the pathogenesis of acute coronary syndromes. Thrombosis Research, 2007, 120, 819-847.	0.8	115
64	Non-vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart failure: a systemic review and meta-analysis of randomized trials. European Journal of Heart Failure, 2015, 17, 1192-1200.	2.9	113
65	document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulaci3n Card3aca y. Europace, 2017, 19, 1757-1758.	0.7	107
66	Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. European Heart Journal, 2017, 38, ehw069.	1.0	106
67	Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force. Europace, 2014, 16, 1655-1673.	0.7	105
68	Diving to the foot of an iceberg: The SEARCH for undiagnosed atrial fibrillation. Thrombosis and Haemostasis, 2014, 112, 1-3.	1.8	101
69	Evaluation of the HAS-BLED, ATRIA, and ORBIT Bleeding Risk Scores in Patients with Atrial Fibrillation Taking Warfarin. American Journal of Medicine, 2016, 129, 600-607.	0.6	101
70	Does Warfarin for Stroke Thromboprophylaxis Protect Against MI in Atrial Fibrillation Patients?. American Journal of Medicine, 2010, 123, 785-789.	0.6	100
71	Comparison of the CHADS2, CHA2DS2-VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: The AMADEUS trial. Thrombosis and Haemostasis, 2013, 110, 1074-1079.	1.8	98
72	Effects of cognitive behavioural therapy for depression in heart failure patients: a systematic review and meta-analysis. Heart Failure Reviews, 2017, 22, 731-741.	1.7	98

#	ARTICLE	IF	CITATIONS
73	Bleeding risk assessment in atrial fibrillation: observations on the use and misuse of bleeding risk scores. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 1711-1714.	1.9	97
74	Ejection fraction and outcomes in patients with atrial fibrillation and heart failure: the Loire Valley Atrial Fibrillation Project. <i>European Journal of Heart Failure</i> , 2012, 14, 295-301.	2.9	96
75	Risk Factors for Stroke and Thromboembolism in Relation to Age Among Patients With Atrial Fibrillation. <i>Chest</i> , 2012, 141, 147-153.	0.4	96
76	Improving Survival of Malignant Hypertension Patients Over 40 Years. <i>American Journal of Hypertension</i> , 2009, 22, 1199-1204.	1.0	95
77	Integrating new approaches to atrial fibrillation management: the 6th AFNET/EHRA Consensus Conference. <i>Europace</i> , 2018, 20, 395-407.	0.7	95
78	Illness perceptions, affective response, and health-related quality of life in patients with atrial fibrillation. <i>Journal of Psychosomatic Research</i> , 2009, 66, 203-210.	1.2	89
79	Renal function and non-vitamin K oral anticoagulants in comparison with warfarin on safety and efficacy outcomes in atrial fibrillation patients: a systemic review and meta-regression analysis. <i>Clinical Research in Cardiology</i> , 2015, 104, 418-429.	1.5	87
80	Pre-participation cardiovascular evaluation for athletic participants to prevent sudden death: Position paper from the EHRA and the EACPR, branches of the ESC. Endorsed by APHRS, HRS, and SOLAECE. <i>Europace</i> , 2017, 19, euw243.	0.7	86
81	Comprehensive Management With the ABC (Atrial Fibrillation Better Care) Pathway in Clinically Complex Patients With Atrial Fibrillation: A Post Hoc Ancillary Analysis From the AFFIRM Trial. <i>Journal of the American Heart Association</i> , 2020, 9, e014932.	1.6	84
82	European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS). <i>European Journal of Preventive Cardiology</i> , 2017, 24, 4-40.	0.8	83
83	Comprehensive risk reduction in patients with atrial fibrillation: Emerging diagnostic and therapeutic options. <i>Thrombosis and Haemostasis</i> , 2011, 106, 1012-1019..	1.8	81
84	Regular Bleeding Risk Assessment Associated with Reduction in Bleeding Outcomes: The mAFA-II Randomized Trial. <i>American Journal of Medicine</i> , 2020, 133, 1195-1202.e2.	0.6	80
85	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: what is the best practice?. <i>Europace</i> , 2018, 20, 1399-1421.	0.7	75
86	Renal function and outcomes in anticoagulated patients with non-valvular atrial fibrillation: the AMADEUS trial. <i>European Heart Journal</i> , 2013, 34, 3572-3579.	1.0	74
87	Vascular Disease and Stroke Risk in Atrial Fibrillation: A Nationwide Cohort Study. <i>American Journal of Medicine</i> , 2012, 125, 826.e13-826.e23.	0.6	73
88	Duration of Diabetes Mellitus and Risk of Thromboembolism and Bleeding in Atrial Fibrillation. <i>Stroke</i> , 2015, 46, 2168-2174.	1.0	72
89	Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm. A Joint Consensus Document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis. <i>European Journal of Heart Failure</i> , 2012, 14, 681-695.	2.9	71
90	Female gender is a risk factor for stroke and thromboembolism in atrial fibrillation patients. <i>Thrombosis and Haemostasis</i> , 2009, 101, 802-805.	1.8	70

#	ARTICLE	IF	CITATIONS
91	Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1. <i>European Heart Journal</i> , 2016, 38, ehv643.	1.0	69
92	Assessing the Risk of Bleeding in Patients With Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2012, 5, 941-948.	2.1	68
93	Management of asymptomatic arrhythmias: a European Heart Rhythm Association (EHRA) consensus document, endorsed by the Heart Failure Association (HFA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa (CASSA), and Latin America Heart Rhythm Society (LAHRS). <i>Europace</i> , 2019, 21, 844-845.	0.7	68
94	Pattern of atrial fibrillation and risk of outcomes: The Loire Valley Atrial Fibrillation Project. <i>International Journal of Cardiology</i> , 2013, 167, 2682-2687.	0.8	67
95	Performance of the HEMORR2HAGES, ATRIA, and HAS-BLED Bleeding Risk Prediction Scores in Nonwarfarin Anticoagulated Atrial Fibrillation Patients. <i>Journal of the American College of Cardiology</i> , 2013, 61, 386-387.	1.2	67
96	European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS). <i>Europace</i> , 2017, 19, euw242.	0.7	67
97	Characterisation and validity of inflammatory biomarkers in the prediction of post-operative atrial fibrillation in coronary artery disease patients. <i>Thrombosis and Haemostasis</i> , 2010, 104, 122-127.	1.8	66
98	Atrial fibrillation as a risk factor for cognitive impairment: a semi-systematic review. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2013, 106, 795-802.	0.2	66
99	European Heart Rhythm Association/Heart Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. <i>Europace</i> , 2016, 18, 12-36.	0.7	66
100	Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation. <i>The Cochrane Library</i> , 2017, 2017, CD008600.	1.5	66
101	Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm. <i>Thrombosis and Haemostasis</i> , 2012, 108, 1009-1022.	1.8	65
102	Patient's values and preferences for stroke prevention in atrial fibrillation: balancing stroke and bleeding risk with oral anticoagulation. <i>Thrombosis and Haemostasis</i> , 2014, 112, 381-383.	1.8	64
103	Thromboprophylaxis in atrial fibrillation and association with cognitive decline: systematic review. <i>Age and Ageing</i> , 2016, 45, 767-775.	0.7	64
104	Quality indicators for the care and outcomes of adults with atrial fibrillation. <i>Europace</i> , 2021, 23, 494-495.	0.7	64
105	Mobile Apps to Improve Medication Adherence in Cardiovascular Disease: Systematic Review and Meta-analysis. <i>Journal of Medical Internet Research</i> , 2021, 23, e24190.	2.1	64
106	Stroke Risk Stratification in a Real-World Elderly Anticoagulated Atrial Fibrillation Population. <i>Journal of Cardiovascular Electrophysiology</i> , 2011, 22, 25-30.	0.8	63
107	Myocardial Ischemic Events in Real World Patients with Atrial Fibrillation Treated with Dabigatran or Warfarin. <i>American Journal of Medicine</i> , 2014, 127, 329-336.e4.	0.6	63
108	Prevalence and clinical outcomes of myocarditis and pericarditis in 718,365 COVID-19 patients. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13679.	1.7	63

#	ARTICLE	IF	CITATIONS
109	In-hospital symptoms of depression do not predict mortality 3 years after myocardial infarction. <i>International Journal of Epidemiology</i> , 2002, 31, 1179-1182.	0.9	61
110	The Impact of Heart Failure and Left Ventricular Dysfunction in Predicting Stroke, Thromboembolism, and Mortality in Atrial Fibrillation Patients: A Systematic Review. <i>Clinical Therapeutics</i> , 2014, 36, 1135-1144.	1.1	57
111	Residual Risk of Stroke and Death in Anticoagulated Patients According to the Type of Atrial Fibrillation. <i>Stroke</i> , 2015, 46, 2523-2528.	1.0	57
112	Impact of advanced age on management and prognosis in atrial fibrillation: insights from a population-based study in general practice. <i>Age and Ageing</i> , 2015, 44, 874-878.	0.7	57
113	Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2013, 109, 328-336.	1.8	56
114	Mobile Health (mHealth) technology for improved screening, patient involvement and optimising integrated care in atrial fibrillation: The mAFA (mAFâ€App) II randomised trial. <i>International Journal of Clinical Practice</i> , 2019, 73, e13352.	0.8	56
115	The Impact of Smoking on Thromboembolism and Mortality in Patients With Incident Atrial Fibrillation. <i>Chest</i> , 2014, 145, 559-566.	0.4	54
116	Patientsâ€™ and health professionalsâ€™ views and experiences of atrial fibrillation and oral-anticoagulant therapy: A qualitative meta-synthesis. <i>Patient Education and Counseling</i> , 2012, 88, 330-337.	1.0	53
117	Do depression and anxiety predict recurrent coronary events 12 months after myocardial infarction?. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2000, 93, 739-744.	0.2	52
118	Best Practice for Atrial Fibrillation Patient Education. <i>Current Pharmaceutical Design</i> , 2014, 21, 533-543.	0.9	52
119	Simplifying stroke risk stratification in atrial fibrillation patients: implications of the CHA2DS2-VASc risk stratification scores. <i>Age and Ageing</i> , 2010, 39, 533-535.	0.7	51
120	Alcohol intake and prognosis of atrial fibrillation. <i>Heart</i> , 2013, 99, 1093-1099.	1.2	51
121	Increased burden of comorbidities and risk of cardiovascular death in atrial fibrillation patients in Europe over ten years: A comparison between EORP-AF pilot and EHS-AF registries. <i>European Journal of Internal Medicine</i> , 2018, 55, 28-34.	1.0	51
122	Development of an international standard set of outcome measures for patients with atrial fibrillation: a report of the International Consortium for Health Outcomes Measurement (ICHOM) atrial fibrillation working group. <i>European Heart Journal</i> , 2020, 41, 1132-1140.	1.0	50
123	Major Bleeding in Patients with Non-Valvular Atrial Fibrillation: Impact of Time in Therapeutic Range on Contemporary Bleeding Risk Scores. <i>Scientific Reports</i> , 2016, 6, 24376.	1.6	49
124	Stroke Prevention, Evaluation of Bleeding Risk, and Anticoagulant Treatment Management in Atrial Fibrillation Contemporary International Guidelines. <i>Canadian Journal of Cardiology</i> , 2019, 35, 619-633.	0.8	48
125	The impact of atherosclerotic vascular disease in predicting a stroke, thromboembolism and mortality in atrial fibrillation patients: a systematic review. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 975-987.	1.9	47
126	Home-based versus hospital-based cardiac rehabilitation after myocardial infarction or revascularisation: design and rationale of the Birmingham Rehabilitation Uptake Maximisation Study (BRUM): a randomised controlled trial [ISRCTN72884263]. <i>BMC Cardiovascular Disorders</i> , 2003, 3, 10.	0.7	46

#	ARTICLE	IF	CITATIONS
127	Improving the Prescription of Oral Anticoagulants in Atrial Fibrillation: A Systematic Review. <i>Thrombosis and Haemostasis</i> , 2019, 119, 294-307.	1.8	46
128	Barriers to Anticoagulation in Patients With Atrial Fibrillation. <i>Stroke</i> , 2008, 39, 7-9.	1.0	45
129	Stroke and Bleeding Risk in Atrial Fibrillation: Navigating the Alphabet Soup of Risk Score Acronyms (CHADS ₂ , CHA ₂ DS ₂ -ASc, R ₂ -CHADS ₂), Tj ETQq7 1 0.784314 rgB		
130	2021 ISHNE/HRS/EHRA/APHRS Expert Collaborative Statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals: From the International Society for Holter and Noninvasive Electrocardiology/Heart Rhythm Society/European Heart Rhythm Association/Asia-Pacific Heart Rhythm Society. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021, 14, e009204.	2.1	45
131	Bleeding Risk Scores in Atrial Fibrillation and Venous Thromboembolism. <i>American Journal of Cardiology</i> , 2017, 120, 1139-1145.	0.7	44
132	Patient-Reported Outcomes for Quality of Life Assessment in Atrial Fibrillation: A Systematic Review of Measurement Properties. <i>PLoS ONE</i> , 2016, 11, e0165790.	1.1	44
133	Dabigatran and Warfarin for Secondary Prevention of Stroke in Atrial Fibrillation Patients: A Nationwide Cohort Study. <i>American Journal of Medicine</i> , 2014, 127, 1172-1178.e5.	0.6	43
134	Patients' and physicians' experiences of atrial fibrillation consultations and anticoagulation decision-making: A multi-perspective IPA design. <i>Psychology and Health</i> , 2016, 31, 436-455.	1.2	43
135	Cognitive Behavioral Therapy for Depression, Anxiety, and Stress in Caregivers of Dementia Patients: A Systematic Review and Meta-Analysis. <i>Gerontologist</i> , The, 2019, 59, e343-e362.	2.3	43
136	Integrated care for optimizing the management of stroke and associated heart disease: a position paper of the European Society of Cardiology Council on Stroke. <i>European Heart Journal</i> , 2022, 43, 2442-2460.	1.0	43
137	Mobile health solutions for atrial fibrillation detection and management: a systematic review. <i>Clinical Research in Cardiology</i> , 2022, 111, 479-491.	1.5	42
138	Antithrombotic Therapy in Atrial Fibrillation Associated with Valvular Heart Disease: Executive Summary of a Joint Consensus Document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, Endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Es. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2215-2236.	1.8	41
139	Use of leadless pacemakers in Europe: results of the European Heart Rhythm Association survey. <i>Europace</i> , 2018, 20, 555-559.	0.7	41
140	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: What is the best practice?. <i>Journal of Arrhythmia</i> , 2018, 34, 99-123.	0.5	41
141	Incident Heart Failure in Patients With Rheumatoid Arthritis: A Nationwide Cohort Study. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	40
142	Beyond the 2020 guidelines on atrial fibrillation of the European society of cardiology. <i>European Journal of Internal Medicine</i> , 2021, 86, 1-11.	1.0	40
143	Psychological interventions for depression in heart failure. <i>The Cochrane Library</i> , 2005, , CD003329.	1.5	38
144	Alcohol and Illicit Drug Use as Precipitants of Atrial Fibrillation in Young Adults: A Case Series and Literature Review. <i>American Journal of Medicine</i> , 2009, 122, 851-856.e3.	0.6	37

#	ARTICLE	IF	CITATIONS
145	Treatment of hypertension in peripheral arterial disease. The Cochrane Library, 2013, , CD003075.	1.5	37
146	Development of a Novel Composite Stroke and Bleeding Risk Score in Patients With Atrial Fibrillation. Chest, 2013, 144, 1839-1847.	0.4	37
147	Optimising stroke prevention in patients with atrial fibrillation: application of the GRASP-AF audit tool in a UK general practice cohort. British Journal of General Practice, 2015, 65, e16-e23.	0.7	37
148	Quality of life in older people with atrial fibrillation. Journal of Interventional Cardiac Electrophysiology, 2009, 25, 37-42.	0.6	36
149	Assessing bleeding risk in atrial fibrillation with the HAS-BLED and ORBIT scores: clinical application requires focus on the reversible bleeding risk factors. European Heart Journal, 2015, 36, ehv415.	1.0	36
150	Stroke-Heart Syndrome: Incidence and Clinical Outcomes of Cardiac Complications Following Stroke. Stroke, 2022, 53, 1759-1763.	1.0	36
151	Prognostic role of plasma von Willebrand factor and soluble E-selectin levels for future cardiovascular events in a "real-world" community cohort of patients with atrial fibrillation. European Journal of Clinical Investigation, 2013, 43, 1032-1038.	1.7	35
152	Stroke Prevention With Oral Anticoagulation Therapy in Patients With Atrial Fibrillation. Circulation Journal, 2013, 77, 1380-1388.	0.7	35
153	Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation. , 2013, , CD008600.		35
154	Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants vs. Warfarin in Japanese Patients With Atrial Fibrillation. Circulation Journal, 2015, 79, 339-345.	0.7	35
155	Patients' experiences of atrial fibrillation and non-vitamin K antagonist oral anticoagulants (NOACs), and their educational needs: A qualitative study. Thrombosis Research, 2017, 153, 19-27.	0.8	35
156	Global Use of Idarucizumab in Clinical Practice: Outcomes of the RE-VECTO Surveillance Program. Thrombosis and Haemostasis, 2020, 120, 027-035.	1.8	35
157	The Value of the European Society of Cardiology Guidelines for Refining Stroke Risk Stratification in Patients With Atrial Fibrillation Categorized as Low Risk Using the Anticoagulation and Risk Factors in Atrial Fibrillation Stroke Score. Chest, 2014, 146, 1337-1346.	0.4	34
158	Guideline-Adherent Antithrombotic Treatment Improves Outcomes in Patients With Atrial Fibrillation. Mayo Clinic Proceedings, 2017, 92, 1203-1213.	1.4	34
159	Recruitment of ethnic minority patients to a cardiac rehabilitation trial: The Birmingham Rehabilitation Uptake Maximisation (BRUM) study [ISRCTN72884263]. BMC Medical Research Methodology, 2005, 5, 18.	1.4	32
160	Stroke and Bleeding Risk in Atrial Fibrillation. Korean Circulation Journal, 2014, 44, 281.	0.7	32
161	Self-reported physical activity and major adverse events in patients with atrial fibrillation: a report from the EURObservational Research Programme Pilot Survey on Atrial Fibrillation (EORP-AF) General Registry. Europace, 2017, 19, euw150.	0.7	32
162	TRial of an Educational intervention on patients' knowledge of Atrial fibrillation and anticoagulant therapy, INR control, and outcome of Treatment with warfarin (TREAT). BMC Cardiovascular Disorders, 2010, 10, 21.	0.7	31

#	ARTICLE	IF	CITATIONS
163	Matching the NOAC to the Patient. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2282-2284.	1.2	31
164	Chronic Kidney Disease, Time in Therapeutic Range and Adverse Clinical Outcomes in Anticoagulated Patients with Non-valvular Atrial Fibrillation: Observations from the SPORTIF Trials. <i>EBioMedicine</i> , 2016, 8, 309-316.	2.7	31
165	Atrial fibrillation patient preferences for oral anticoagulation and stroke knowledge: Results of a conjoint analysis. <i>Clinical Cardiology</i> , 2018, 41, 855-861.	0.7	31
166	Are angiotensin-converting enzyme inhibitors and angiotensin receptor blockers safe in pregnancy: a report of ninety-one pregnancies. <i>Journal of Hypertension</i> , 2011, 29, 396-399.	0.3	30
167	Matrix metalloproteinases and their tissue inhibitors in hypertension-related pregnancy complications. <i>Journal of Human Hypertension</i> , 2013, 27, 72-78.	1.0	30
168	Atrial fibrillation and the risk of 30-day incident thromboembolic events, and mortality in adults 50 years with COVID-19. <i>Journal of Arrhythmia</i> , 2021, 37, 231-237.	0.5	30
169	Routine versus aggressive upstream rhythm control for prevention of early atrial fibrillation in heart failure: background, aims and design of the RACE 3 study. <i>Netherlands Heart Journal</i> , 2013, 21, 354-363.	0.3	29
170	Recent Developments in Understanding Epidemiology and Risk Determinants of Atrial Fibrillation as a Cause of Stroke. <i>Canadian Journal of Cardiology</i> , 2013, 29, S4-S13.	0.8	29
171	Secondary Versus Primary Stroke Prevention in Atrial Fibrillation: Insights From the Darlington Atrial Fibrillation Registry. <i>Stroke</i> , 2017, 48, 2198-2205.	1.0	29
172	Etiologic Workup in Cases of Cryptogenic Stroke. <i>Stroke</i> , 2020, 51, 1419-1427.	1.0	29
173	2021 ISHNE/ HRS/ EHRA/ APHRS collaborative statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals. <i>Annals of Noninvasive Electrocardiology</i> , 2021, 26, e12795.	0.5	29
174	An evaluation of the Minnesota Living with Heart Failure Questionnaire using Rasch analysis. <i>Quality of Life Research</i> , 2014, 23, 1753-1765.	1.5	28
175	European Heart Rhythm Association (EHRA) consensus document on the management of supraventricular arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulaci3n Cardiac y Electrofisiologia (SOLAEFC). <i>European Heart Journal</i> . 2018. 39, ehw455.	1.0	28
176	Endothelial dysfunction in hypertension in pregnancy: associations between circulating endothelial cells, circulating progenitor cells and plasma von Willebrand factor. <i>Clinical Research in Cardiology</i> , 2011, 100, 531-537.	1.5	27
177	Psychological interventions for depression in adolescent and adult congenital heart disease. <i>The Cochrane Library</i> , 2013, , CD004372.	1.5	27
178	Combined anticoagulation and antiplatelet therapy for high-risk patients with atrial fibrillation: a systematic review. <i>Health Technology Assessment</i> , 2013, 17, 1-188.	1.3	27
179	The Effects of Implementing a Mobile Health Technology Supported Pathway on Atrial Fibrillation-Related Adverse Events Among Patients With Multimorbidity. <i>JAMA Network Open</i> , 2021, 4, e2140071.	2.8	27
180	Circulating Endothelial Cells, Arterial Stiffness, and Cardiovascular Risk Stratification in Hypertension. <i>Chest</i> , 2007, 132, 1540-1547.	0.4	26

#	ARTICLE	IF	CITATIONS
181	Bleeding risks with combination of oral anticoagulation plus antiplatelet therapy: Is clopidogrel any safer than aspirin when combined with warfarin?. <i>Thrombosis and Haemostasis</i> , 2008, 100, 955-957.	1.8	26
182	Bleeding Risk in Patients With Atrial Fibrillation. <i>Chest</i> , 2011, 140, 146-155.	0.4	26
183	Modern Management of Atrial Fibrillation Requires Initial Identification of "Low-Risk" Patients Using the CHA ₂ DS ₂ -VASc Score, and Not Focusing on "High-Risk" Prediction. <i>Circulation Journal</i> , 2014, 78, 1843-1845.	0.7	26
184	Gender differences in stroke prevention in atrial fibrillation in general practice: using the GRASP-AF audit tool. <i>International Journal of Clinical Practice</i> , 2015, 69, 840-845.	0.8	25
185	Relation of Nonvalvular Atrial Fibrillation to Body Mass Index (from the SPORTIF Trials). <i>American Journal of Cardiology</i> , 2016, 118, 72-78.	0.7	25
186	Comparison of bleeding risk scores in patients with atrial fibrillation: insights from the RE-LY trial. <i>Journal of Internal Medicine</i> , 2018, 283, 282-292.	2.7	25
187	Lipid levels, atrial fibrillation and the impact of age: Results from the LIPIDOGram2015 study. <i>Atherosclerosis</i> , 2020, 312, 16-22.	0.4	25
188	The Euro Heart Survey and EURObservational Research Programme (EORP) in atrial fibrillation registries: contribution to epidemiology, clinical management and therapy of atrial fibrillation patients over the last 20 years. <i>Internal and Emergency Medicine</i> , 2020, 15, 1183-1192.	1.0	25
189	Higher Mortality of Ischaemic Stroke Patients Hospitalized with COVID-19 Compared to Historical Controls. <i>Cerebrovascular Diseases</i> , 2021, 50, 326-331.	0.8	25
190	Real-world applicability and impact of early rhythm control for European patients with atrial fibrillation: a report from the ESC-EHRA EORP-AF Long-Term General Registry. <i>Clinical Research in Cardiology</i> , 2022, 111, 70-84.	1.5	25
191	RCPE UK Consensus Conference on "Approaching the comprehensive management. <i>Journal of the Royal College of Physicians of Edinburgh</i> , The, 2012, 42, 34-35.	0.2	24
192	Use of the SAME-TT2R2 score to predict anticoagulation control in atrial fibrillation and venous thromboembolism patients receiving vitamin K antagonists: A review. <i>Heart Rhythm</i> , 2018, 15, 615-623.	0.3	23
193	Mobile health applications for managing atrial fibrillation for healthcare professionals and patients: a systematic review. <i>Europace</i> , 2020, 22, 1567-1578.	0.7	23
194	Educational Impact on Apixaban Adherence in Atrial Fibrillation (the AEGEAN STUDY): A Randomized Clinical Trial. <i>American Journal of Cardiovascular Drugs</i> , 2020, 20, 61-71.	1.0	22
195	Atrial fibrillation in low- and middle-income countries: a narrative review. <i>European Heart Journal Supplements</i> , 2020, 22, O61-O77.	0.0	22
196	Impact of clinical phenotypes on management and outcomes in European atrial fibrillation patients: a report from the ESC-EHRA EURObservational Research Programme in AF (EORP-AF) General Long-Term Registry. <i>BMC Medicine</i> , 2021, 19, 256.	2.3	22
197	Maintaining Therapeutic Anticoagulation. <i>Chest</i> , 2007, 131, 1277-1279.	0.4	21
198	Relation of the SAME-TT 2 R 2 score to quality of anticoagulation control and thromboembolic events in atrial fibrillation patients: Observations from the SPORTIF trials. <i>International Journal of Cardiology</i> , 2016, 216, 168-172.	0.8	21

#	ARTICLE	IF	CITATIONS
199	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: what is the best practice?. <i>Heart Rhythm</i> , 2018, 15, e37-e60.	0.3	21
200	2021 ISHNE/HRS/EHRA/APHRS collaborative statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals. <i>Journal of Arrhythmia</i> , 2021, 37, 271-319.	0.5	21
201	The Atrial Fibrillation Better Care pathway for managing atrial fibrillation: a review. <i>Europace</i> , 2021, 23, 1511-1527.	0.7	21
202	Triple antithrombotic therapy in atrial fibrillation patients with acute coronary syndromes or undergoing percutaneous coronary intervention or transcatheter aortic valve replacement. <i>EuroIntervention</i> , 2015, 10, 1015-1021.	1.4	21
203	Female gender is a risk factor for stroke and thromboembolism in atrial fibrillation patients. <i>Thrombosis and Haemostasis</i> , 2009, 101, 802-5.	1.8	21
204	Optimizing stroke prevention in atrial fibrillation: better adherence and compliance from patients and physicians leads to better outcomes. <i>Europace</i> , 2015, 17, 507-508.	0.7	20
205	Can We IMPROVE Bleeding Risk Assessment for Acutely Ill, Hospitalized Medical Patients?. <i>Chest</i> , 2011, 139, 10-13.	0.4	19
206	Adolescentsâ€™ and Young Adultsâ€™ Lived Experiences Following Venous Thromboembolism. <i>Nursing Research</i> , 2016, 65, 455-464.	0.8	19
207	Anti-thrombotic therapy for atrial fibrillation and patients' preferences for treatment. <i>Age and Ageing</i> , 2005, 34, 1-3.	0.7	18
208	Bleeding Risk Stratification Models in Deciding on Anticoagulation in Patients With Atrial Fibrillation. <i>Chest</i> , 2006, 130, 1296-1299.	0.4	18
209	Amiloride 10 mg is less effective than spironolactone 25 mg in patients with hypertension resistant to a multidrug regime including an angiotensin-blocking agent. <i>Journal of Hypertension</i> , 2007, 25, 2515-2516.	0.3	18
210	Net clinical benefit of edoxaban versus no treatment in a "real world" atrial fibrillation population: A modelling analysis based on a nationwide cohort study. <i>International Journal of Cardiology</i> , 2015, 201, 693-698.	0.8	18
211	Stroke and death in elderly patients with atrial fibrillation in Japan compared with the United Kingdom. <i>Heart</i> , 2016, 102, 1878-1882.	1.2	18
212	International Collaborative Partnership for the Study of Atrial Fibrillation (INTERAF): Rationale, Design, and Initial Descriptives. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	18
213	Clinical Features and Prognosis in Patients with Atrial Fibrillation and Prior Stroke: Comparing the Fushimi and Darlington AF Registries. <i>EBioMedicine</i> , 2017, 18, 199-203.	2.7	18
214	"Real-world" observational studies in arrhythmia research: data sources, methodology, and interpretation. A position document from European Heart Rhythm Association (EHRA), endorsed by Heart Rhythm Society (HRS), Asia-Pacific HRS (APHRS), and Latin America HRS (LAHRS). <i>Europace</i> , 2020, 22, 831-832.	0.7	18
215	Stroke and Bleeding Risk Assessments in Patients With Atrial Fibrillation: Concepts and Controversies. <i>Frontiers in Medicine</i> , 2020, 7, 54.	1.2	18
216	Exercise-Based Cardiac Rehabilitation and All-Cause Mortality Among Patients With Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2021, 10, e020804.	1.6	18

#	ARTICLE	IF	CITATIONS
217	Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic. <i>International Journal of Clinical Practice</i> , 2015, 69, 1341-1348.	0.8	17
218	Patients' Perceptions of Atrial Fibrillation, Stroke Risk, and Oral Anticoagulation Treatment: An International Survey. <i>TH Open</i> , 2018, 02, e233-e241.	0.7	17
219	Stroke and bleeding risk stratification in atrial fibrillation: a critical appraisal. <i>European Heart Journal Supplements</i> , 2020, 22, O14-O27.	0.0	17
220	Female sex as a risk factor for thromboembolism and death in patients with incident atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2014, 112, 789-795.	1.8	16
221	A bifactor model of the Beck Depression Inventory and its association with medical prognosis after myocardial infarction.. <i>Health Psychology</i> , 2016, 35, 614-624.	1.3	16
222	Contra: "Anti-platelet therapy is an alternative to oral anticoagulation for atrial fibrillation" <i>Thrombosis and Haemostasis</i> , 2009, 102, 914-915.	1.8	15
223	Use of psychotropic drugs following venous thromboembolism in youth. A nationwide cohort study. <i>Thrombosis Research</i> , 2015, 135, 643-647.	0.8	15
224	Temporal and venepuncture-related decline in circulating endothelial cell capture from mixed venous blood. <i>Journal of Thrombosis and Thrombolysis</i> , 2006, 22, 125-131.	1.0	14
225	The ATRIA Risk Scheme to Predict Warfarin-Associated Hemorrhage. <i>Journal of the American College of Cardiology</i> , 2012, 59, 194-195.	1.2	14
226	Assessment of stroke risk in Middle Eastern patients with atrial fibrillation: The Gulf SAFE registry. <i>International Journal of Cardiology</i> , 2013, 168, 1644-1646.	0.8	14
227	Utilization and perception of same-day discharge in electrophysiological procedures and device implantations: an EHRA survey. <i>Europace</i> , 2021, 23, 149-156.	0.7	14
228	Cross-cultural adaptation into Punjabi of the English version of the Hospital Anxiety and Depression Scale. <i>BMC Psychiatry</i> , 2007, 7, 5.	1.1	13
229	Advancing age and bleeding risk are the strongest barriers to anticoagulant prescription in atrial fibrillation. <i>Age and Ageing</i> , 2011, 40, 653-655.	0.7	13
230	Apixaban Compared With Warfarin for Stroke Prevention in Atrial Fibrillation. <i>Circulation</i> , 2013, 127, 2163-2165.	1.6	13
231	Patient Guide for Taking the Non"Vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation. <i>Circulation</i> , 2015, 131, e412-5.	1.6	13
232	Clinicians"™ views and experiences of prescribing oral anticoagulants for stroke prevention in atrial fibrillation: A qualitative meta-synthesis. <i>PLoS ONE</i> , 2020, 15, e0232484.	1.1	13
233	Associations between COVID-19 and 30-day thromboembolic events and mortality in people with dementia receiving antipsychotic medications. <i>Pharmacological Research</i> , 2021, 167, 105534.	3.1	13
234	Epidemiology of subclinical atrial fibrillation in patients with cardiac implantable electronic devices: A systematic review and meta-regression. <i>European Journal of Internal Medicine</i> , 2022, 103, 84-94.	1.0	13

#	ARTICLE	IF	CITATIONS
235	Anticoagulation control in different ethnic groups receiving vitamin K antagonist therapy for stroke prevention in atrial fibrillation. <i>Thrombosis Research</i> , 2020, 192, 12-20.	0.8	12
236	Atrial fibrillation and stroke risk prevention in real-life clinical practice. <i>Thrombosis and Haemostasis</i> , 2009, 101, 415-416.	1.8	12
237	Dabigatran in atrial fibrillation: balancing secondary stroke prevention against bleeding risk. <i>Lancet Neurology</i> , The, 2010, 9, 1140-1142.	4.9	11
238	Lack of impact of pulse pressure on outcomes in patients with malignant phase hypertension. <i>Journal of Hypertension</i> , 2012, 30, 974-979.	0.3	11
239	The Compelling Issue of Nonvitamin K Antagonist Oral Anticoagulant Adherence in Atrial Fibrillation Patients: A Systematic Need for New Strategies. <i>Thrombosis and Haemostasis</i> , 2020, 120, 369-371.	1.8	11
240	Peri-procedural management, implantation feasibility, and short-term outcomes in patients undergoing implantation of leadless pacemakers: European Snapshot Survey. <i>Europace</i> , 2020, 22, 833-838.	0.7	11
241	Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: A Position Paper from the ESC Working Group on Thrombosis, in collaboration with the European Heart Rhythm Association, the Association for Acute CardioVascular Care and the Asia-Pacific Heart Rhythm Society. <i>Europace</i> , 2022, 24, 1844-1871.	0.7	11
242	Interactive Remote Patient Monitoring Devices for Managing Chronic Health Conditions: Systematic Review and Meta-analysis. <i>Journal of Medical Internet Research</i> , 2022, 24, e35508.	2.1	11
243	The Quest for New Anticoagulants: From Clinical Development to Clinical Practice. <i>Cardiovascular Therapeutics</i> , 2011, 29, e12-e22.	1.1	10
244	Stroke risk stratification scores in atrial fibrillation: current recommendations for clinical practice and future perspectives. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 77-90.	0.6	10
245	Streamlining primary and secondary care management pathways for stroke prevention in atrial fibrillation. <i>European Heart Journal</i> , 2017, 38, 2980-2982.	1.0	10
246	Individual depressive symptoms and all-cause mortality In 6673 patients with myocardial infarction: Heterogeneity across age and sex subgroups. <i>Journal of Affective Disorders</i> , 2018, 228, 178-185.	2.0	10
247	Innovative strategies to improve adherence to non-vitamin K antagonist oral anticoagulants for stroke prevention in atrial fibrillation. <i>European Heart Journal</i> , 2018, 39, 1404-1406.	1.0	10
248	Antithrombotic treatment in patients with atrial fibrillation and acute coronary syndromes: results of the European Heart Rhythm Association survey. <i>Europace</i> , 2019, 21, 1116-1125.	0.7	10
249	Mobile health technology facilitates population screening and integrated care management in patients with atrial fibrillation. <i>European Heart Journal</i> , 2020, 41, 1617-1619.	1.0	10
250	2021 ISHNE/HRS/EHRA/APHRS Collaborative Statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals. <i>Cardiovascular Digital Health Journal</i> , 2021, 2, 4-54.	0.5	10
251	Managing Uncertainty: Physicians' Decision Making for Stroke Prevention for Patients with Atrial Fibrillation and Intracerebral Hemorrhage. <i>Thrombosis and Haemostasis</i> , 2022, 122, 1603-1611.	1.8	10
252	Oral anticoagulants and outcomes in adults ≥80 years with atrial fibrillation: A global federated health network analysis. <i>Journal of the American Geriatrics Society</i> , 2022, 70, 2386-2392.	1.3	10

#	ARTICLE	IF	CITATIONS
253	Impact of symptom control on health-related quality of life in atrial fibrillation patients: the psychologist's viewpoint. <i>Europace</i> , 2010, 12, 608-610.	0.7	9
254	Soluble Fas and Fas Ligand in Pregnancy. <i>Angiology</i> , 2012, 63, 35-38.	0.8	9
255	Atrial Fibrillation in Cryptogenic Stroke. <i>Stroke</i> , 2014, 45, 3184-3185.	1.0	9
256	Atrial Fibrillation and Heart Failure: A Bad Combination. <i>American Journal of Cardiology</i> , 2014, 113, 1196-1197.	0.7	9
257	The Role of Acceptance and Commitment Therapy in Cardiovascular and Diabetes Healthcare: A Scoping Review. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 8126.	1.2	9
258	Angiogenin and Hemoxygenase in Pregnancy. <i>Angiology</i> , 2012, 63, 194-198.	0.8	8
259	Letter by Apostolakis et al Regarding Article, "Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation: Validation of the R ² CHADS		

#	ARTICLE	IF	CITATIONS
271	Guideline-Adherent Treatment for Stroke and Death in Atrial Fibrillation Patients From UK and Japanese AF Registries. <i>Circulation Journal</i> , 2019, 83, 2434-2442.	0.7	6
272	Validation of the modified Microlife blood pressure monitor in patients with paroxysmal atrial fibrillation. <i>Clinical Research in Cardiology</i> , 2020, 109, 802-809.	1.5	6
273	Impact of malignancy on outcomes in European patients with atrial fibrillation: A report from the ESC-EHRA EURObservational research programme in atrial fibrillation general long-term registry. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13773.	1.7	6
274	Anticoagulation Control With Vitamin K Antagonists. <i>Chest</i> , 2006, 129, 1122-1124.	0.4	5
275	Anticoagulation for Atrial Fibrillation Patients with CHADS ₂ Score of 1. <i>Journal of Cardiovascular Electrophysiology</i> , 2010, 21, 508-510.	0.8	5
276	Atrial fibrillation and mortality: the impact of antithrombotic therapy. <i>European Heart Journal</i> , 2010, 31, 2075-2076.	1.0	5
277	Stroke prevention in atrial fibrillation patients. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 2331-2350.	0.9	5
278	Angiogenin and apoptosis in hypertension in pregnancy. <i>Pregnancy Hypertension</i> , 2011, 1, 191-196.	0.6	5
279	An epidemic of atrial fibrillation?. <i>Europace</i> , 2011, 13, 1059-1060.	0.7	5
280	Short-Term Effects of Screening for Cardiovascular Risk in the Deaf Community: A Pilot Study. <i>Cardiology Research and Practice</i> , 2011, 2011, 1-5.	0.5	5
281	Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation. <i>Current Problems in Cardiology</i> , 2014, 39, 319-344.	1.1	5
282	Difficult decision making in the management of patients with atrial fibrillation and acute coronary syndrome or invasive cardiovascular interventions: new recommendations for daily practice. <i>Europace</i> , 2015, 17, 1319-1322.	0.7	5
283	Qualitative exploration of the effect of a television soap opera storyline on women with experience of postpartum psychosis. <i>BJPsych Open</i> , 2018, 4, 75-82.	0.3	5
284	Integrated care for the management of atrial fibrillation: what are the key components and important outcomes?. <i>Europace</i> , 2019, 21, 1759-1761.	0.7	5
285	Considerations when choosing an appropriate bleeding risk assessment tool for patients with atrial fibrillation. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 788-790.	1.9	5
286	Cardiac troponins and adverse outcomes in European patients with atrial fibrillation: A report from the ESC-EHRA EORP atrial fibrillation general long-term registry. <i>European Journal of Internal Medicine</i> , 2022, 99, 45-56.	1.0	5
287	Modelling of longitudinal data to predict cardiovascular disease risk: a methodological review. <i>BMC Medical Research Methodology</i> , 2021, 21, 283.	1.4	5
288	Risk of Cerebrovascular Events in Intracerebral Hemorrhage Survivors With Atrial Fibrillation: A Nationwide Cohort Study. <i>Stroke</i> , 2022, 53, 2559-2568.	1.0	5

#	ARTICLE	IF	CITATIONS
289	Effectiveness and Safety of Apixaban in over 3.9 Million People with Atrial Fibrillation: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2022, 11, 3788.	1.0	5
290	Vital exhaustion and cardiovascular disease: Are circulating fibrinogen and D-dimer levels a plausible link?. <i>Stress</i> , 2008, 11, 247-249.	0.8	4
291	Obstructive Sleep Apnea Is a Risk Factor for Stroke and Atrial Fibrillation: Response. <i>Chest</i> , 2010, 138, 239-240.	0.4	4
292	Quality of anticoagulation control in atrial fibrillation. <i>Lancet, The</i> , 2010, 376, 935-937.	6.3	4
293	Executive Summary: European Heart Rhythm Association Consensus Document on the Management of Supraventricular Arrhythmias. <i>Arrhythmia and Electrophysiology Review</i> , 2016, 5, 210.	1.3	4
294	Anticoagulation for Atrial Fibrillation in Older Adults—Using Big Data for Big Questions. <i>Thrombosis and Haemostasis</i> , 2019, 119, 855-857.	1.8	4
295	Practice-derived data on non-vitamin K antagonist oral anticoagulant therapy to complement observations from randomized trials. <i>European Heart Journal Supplements</i> , 2020, 22, 11-112.	0.0	4
296	Antithrombotic therapy for stroke prevention in patients with atrial fibrillation who survive an intracerebral haemorrhage: results of an EHRA survey. <i>Europace</i> , 2021, 23, 806-814.	0.7	4
297	Association of Exercise-Based Cardiac Rehabilitation with Progression of Paroxysmal to Sustained Atrial Fibrillation. <i>Journal of Clinical Medicine</i> , 2021, 10, 435.	1.0	4
298	2021 ISHNE / HRS / EHRA / APHRS Collaborative Statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals. <i>European Heart Journal Digital Health</i> , 2021, 2, 7-48.	0.7	4
299	Prospective randomised trial examining the impact of an educational intervention versus usual care on anticoagulation therapy control based on an SAME-TT ₂ R ₂ score-guided strategy in anticoagulant-naïve Thai patients with atrial fibrillation (TREATS-AF): a study protocol. <i>BMJ Open</i> , 2021, 11, e051987.	0.8	4
300	Exercise-Based Cardiac Rehabilitation Associates with Lower Major Adverse Cardiovascular Events in People with Stroke. <i>Cerebrovascular Diseases</i> , 2022, 51, 488-492.	0.8	4
301	Comparative Analysis of the HAS-BLED Score With Other Bleeding Risk Scores, Using Estimates of Net Reclassification Improvement and Integrated Discrimination Improvement. <i>Journal of the American College of Cardiology</i> , 2011, 58, 1398-1399.	1.2	3
302	Optimising stroke prevention in patients with atrial fibrillation. <i>British Journal of General Practice</i> , 2015, 65, 117-117.	0.7	3
303	Stroke prevention in atrial fibrillation: can we do better?. <i>Nature Reviews Cardiology</i> , 2016, 13, 511-512.	6.1	3
304	Reducing risk of adverse cardiovascular and renal outcomes for patients with atrial fibrillation and type 2 diabetes. <i>European Journal of Heart Failure</i> , 2020, 22, 136-138.	2.9	3
305	Optimization of atrial fibrillation care: management strategies and quality measures. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021, 7, 121-133.	1.8	3
306	Patient Satisfaction: A Key Component in Increasing Treatment Adherence and Persistence. <i>Thrombosis and Haemostasis</i> , 2021, 121, 255-257.	1.8	3

#	ARTICLE	IF	CITATIONS
307	Non-Vitamin K Oral Anticoagulant Drugs for Stroke Prevention in Patients with Atrial Fibrillation and Chronic Kidney Disease. <i>Current Medicinal Chemistry</i> , 2016, 23, 2055-2069.	1.2	3
308	Supermarket/Hypermarket Opportunistic Screening for Atrial Fibrillation (SHOPS-AF): A Mixed Methods Feasibility Study Protocol. <i>Journal of Personalized Medicine</i> , 2022, 12, 578.	1.1	3
309	Impact of anthropometric factors on outcomes in atrial fibrillation patients: analysis on 10â€™220 patients from the European Society of Cardiology (ESC)-European Heart Rhythm Association (EHRA) EurObservational Research Programme on Atrial Fibrillation (EORP-AF) general long-term registry. <i>European Journal of Preventive Cardiology</i> . 0...	0.8	3
310	Effectiveness and Safety of Antithrombotic Medication in Patients With Atrial Fibrillation and Intracranial Hemorrhage: Systematic Review and Meta-Analysis. <i>Stroke</i> , 2022, 53, 3035-3046.	1.0	3
311	The assessment of stroke and bleeding risk in atrial fibrillation: where are we now?. <i>Expert Review of Cardiovascular Therapy</i> , 2010, 8, 1703-1710.	0.6	2
312	CHA 2 DS 2 -VASc Risk Scheme: Response. <i>Chest</i> , 2010, 138, 1020-1021.	0.4	2
313	The HAS-BLED Score and Renal Failure: Response. <i>Chest</i> , 2011, 139, 1249-1250.	0.4	2
314	Bleeding risk during oral anticoagulation therapy for atrial fibrillation. <i>Europace</i> , 2013, 15, 773-774.	0.7	2
315	Does obesity influence target organ damage and outcomes in patients with malignant phase hypertension? The West Birmingham Malignant Hypertension Project. <i>Hypertension Research</i> , 2013, 36, 546-549.	1.5	2
316	Use of the HAS-BLED bleeding score in real-life settings. <i>Thrombosis Research</i> , 2014, 134, 202.	0.8	2
317	The 5-factor ORBIT bleeding score predicted major bleeding at 2 years in patients with atrial fibrillation. <i>Annals of Internal Medicine</i> , 2016, 164, JC11.	2.0	2
318	Use of NOACs in the Peri-Operative Management of Patients with Atrial Fibrillation: To Stop, Bridge or Continue?. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1123-1126.	1.8	2
319	Warfarin Therapy and Improved Anticoagulation Control by Patient Self-Management. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1550-1552.	1.8	2
320	Psychotropic drug use following venous thromboembolism versus diabetes mellitus in adolescence or young adulthood: a Danish nationwide cohort study. <i>BMJ Open</i> , 2019, 9, e026159.	0.8	2
321	Etiologic workup in cases of cryptogenic stroke: protocol for a systematic review and comparison of international clinical practice guidelines. <i>Systematic Reviews</i> , 2019, 8, 331.	2.5	2
322	Homelessness: a â€™cause of the causesâ€™™ of cardiovascular disease?. <i>Heart</i> , 2020, 106, 1456-1457.	1.2	2
323	The potential for photoplethysmographic (PPG)-based smart devices in atrial fibrillation detection. <i>Expert Review of Medical Devices</i> , 2020, 17, 253-255.	1.4	2
324	Atrial fibrillation (chronic). <i>Clinical Evidence</i> , 2015, 2015, .	0.2	2

#	ARTICLE	IF	CITATIONS
325	Warfarinâ€™s Self-Care the Best Care?. <i>Thrombosis and Haemostasis</i> , 2022, 122, 471-474.	1.8	2
326	Worldwide trends in antithrombotic therapy prescribing for atrial fibrillation: observations on the â€˜transition eraâ€™™ to non-vitamin K antagonist oral anticoagulants. <i>Europace</i> , 2022, 24, 871-873.	0.7	2
327	Balancing Thromboembolism and Bleeding Risks. <i>Chest</i> , 2009, 136, 1451-1452.	0.4	1
328	Bleeding risk with oral anticoagulation - new frontiers and new questions. <i>International Journal of Clinical Practice</i> , 2011, 65, 719-721.	0.8	1
329	Strategies to Improve Oral Anticoagulation Management. <i>Chest</i> , 2011, 140, 281-282.	0.4	1
330	C0386 A meta-synthesis of qualitative studies exploring patients' and healthcare professionals views of atrial fibrillation and oral anticoagulant therapy. <i>Thrombosis Research</i> , 2012, 130, S112-S113.	0.8	1
331	Anticoagulation for AF: can we GRASP-AF patients?. <i>Nature Reviews Cardiology</i> , 2013, 10, 241-242.	6.1	1
332	Composite end point analyses of non-vitamin K antagonist oral anticoagulants compared with warfarin in patients with atrial fibrillation. <i>Expert Review of Cardiovascular Therapy</i> , 2015, 13, 1155-1163.	0.6	1
333	Assessing Eligibility for Anticoagulation After Diagnosis of Atrial Fibrillationâ€™Reply. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 949.	3.8	1
334	Lifestyle and risk factor modification for reduction of atrial fibrillation: We could do more. <i>Trends in Cardiovascular Medicine</i> , 2020, 30, 387-388.	2.3	1
335	End-Stage renal disease and 30-day mortality for adults with and without COVID-19. <i>European Journal of Internal Medicine</i> , 2021, 83, 93-95.	1.0	1
336	Atrial fibrillation (chronic). <i>Clinical Evidence</i> , 2011, 2011, .	0.2	1
337	Anticoagulation Control in Older Atrial Fibrillation Patients Receiving Vitamin K Antagonist Therapy for Stroke Prevention. <i>International Journal of Clinical Practice</i> , 2022, 2022, 1-8.	0.8	1
338	Advances in therapy for atrial fibrillation. <i>Therapy: Open Access in Clinical Medicine</i> , 2010, 7, 103-105.	0.2	0
339	Assessing the Performance of the HAS-BLED Score: Response. <i>Chest</i> , 2011, 139, 1248.	0.4	0
340	Optimal Antithrombotic Therapy in Patients Receiving Long-term Oral Anticoagulation Requiring Percutaneous Coronary Intervention. <i>Chest</i> , 2011, 139, 240-243.	0.4	0
341	To the Editorâ€™ Adding renal dysfunction to CHA2DS2-VASc improves stroke prediction postcatheter ablation. <i>Heart Rhythm</i> , 2012, 9, e25.	0.3	0
342	C0320 Oral anticoagulation in atrial fibrillation, the patients and physicians experiences of the consultation: A qualitative study. <i>Thrombosis Research</i> , 2012, 130, S193.	0.8	0

#	ARTICLE	IF	CITATIONS
343	Reply. Journal of the American College of Cardiology, 2013, 61, 482-483.	1.2	0
344	The Reply. American Journal of Medicine, 2014, 127, e21.	0.6	0
345	The Liverpool Centre for Cardiovascular Science. European Heart Journal, 2019, 40, 957-958.	1.0	0
346	Letter by Guo et al Regarding Article, "SUPPORT-AF II: Supporting Use of Anticoagulants Through Provider Profiling of Oral Anticoagulant Therapy for Atrial Fibrillation". Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006635.	0.9	0
347	Haemorrhage risks, patient perspectives, and quality-of-life issues. , 2010, , 35-42.		0
348	Impact of mental health conditions on anticoagulation prescription in people with atrial fibrillation. European Heart Journal Quality of Care & Clinical Outcomes, 2021, , .	1.8	0
349	444 Epidemiology of subclinical atrial fibrillation in patients with cardiac implantable electronic devices: a systematic review and meta-regression. European Heart Journal Supplements, 2021, 23, .	0.0	0